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Embelin inhibits endothelial mitochondrial
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Abstract
In the normal quiescent vasculature, only 0.01% of endothelial
cells (ECs) are proliferating. However, this proportion increases
dramatically following the angiogenic switch during tumor growth
or wound healing. Recent evidence suggests that this angiogenic
switch is accompanied by a metabolic switch. Here, we show that
proliferating ECs increasingly depend on mitochondrial oxidative
phosphorylation (OxPhos) for their increased energy demand.
Under growth conditions, ECs consume three times more oxygen
than quiescent ECs and work close to their respiratory limit. The
increased utilization of the proton motif force leads to a reduced
mitochondrial membrane potential in proliferating ECs and sensi-
tizes to mitochondrial uncoupling. The benzoquinone embelin is a
weak mitochondrial uncoupler that prevents neoangiogenesis
during tumor growth and wound healing by exhausting the low
respiratory reserve of proliferating ECs without adversely affecting
quiescent ECs. We demonstrate that this can be exploited thera-
peutically by attenuating tumor growth in syngenic and xenograft
mouse models. This novel metabolic targeting approach might be
clinically valuable in controlling pathological neoangiogenesis
while sparing normal vasculature and complementing cytostatic
drugs in cancer treatment.
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Introduction
In the normal quiescent vasculature of the adult, it is estimated that
only 0.01% of endothelial cells (ECs) are actively proliferating.
However, the proportion of proliferating ECs increases by several
orders of magnitude following the angiogenic switch during tumor
growth and wound healing (Tannock & Hayashi, 1972; Denekamp &
Hobson, 1982). Yet, rapid tumor cell proliferation results in
decreased blood perfusion because the development of supporting
vasculature lags behind (Shweiki et al, 1992). As a consequence,
the newly formed blood vessels inside the tumor experience nutrient
scarcity, acidosis, and hypoxia (Hirayama et al, 2009). Therefore,
vascular network formation in the tumor environment is dependent
on the ability of ECs to survive and migrate in conditions of low
nutrient availability and hypoxia. To do so, ECs need to be equipped
with metabolic mechanisms to maintain sufficient energy supplies
for growth and proliferation, by utilizing alternative energy
substrates to compete with the metabolic requirements of tumor
cells. Despite immediate access to oxygen in the blood, ECs have
been reported to rely on glycolysis (Dobrina & Rossi, 1983; Kru¨tz-
feldt et al, 1990; Mertens et al, 1990). However, other studies have
claimed that glutamine and fatty acids were more essential
substrates, suggesting an important role for oxidative phosphoryla-
tion (OxPhos) and mitochondrial respiration (Leighton et al, 1987;
Spolarics et al, 1991; Dagher et al, 2001). How the relative contribu-
tion of OxPhos and glycolysis is regulated during angiogenesis in
vivo is only just beginning to be understood. Indeed, recent reports
indicate that the angiogenic switch is accompanied by a metabolic
switch that not only regulates EC metabolism but co-determines
proliferative and quiescent EC phenotypes during vessel sprouting
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(De Bock et al, 2013b). These findings illustrate an unprecedented
level of metabolic control over the proliferative state in ECs during
sprouting angiogenesis.
In this study, we show that the benzoquinone embelin acts on
the metabolic interface between angiogenic and quiescent ECs as a
weak mitochondrial uncoupler. By exhausting the low respiratory
reserve of proliferating ECs, embelin impairs the angiogenic capacity
of proliferating ECs during tumor angiogenesis and wound healing
without adversely affecting quiescent ECs. Embelin was originally
isolated from the fruit of the herbal plant Embelia ribes and has
traditionally been used for its antitumor, antiinflammatory, and
analgesic properties (Chitra et al, 1994). Various potential targets
have been associated with its antitumor activity (Nikolovska-
Coleska et al, 2004; Ahn et al, 2007; Dai et al, 2009; Joy et al,
2010); however, the antiangiogenic properties of embelin have not
been explored further. Our findings point at a specific mode of mito-
chondrial uncoupling by benzoquinones that offers a new approach
to targeting neoangiogenesis. This concept could be clinically valu-
able in controlling pathological neoangiogenesis while minimizing
collateral damage to normal blood vessels.
Results
Embelin treatment inhibits tumor growth in syngenic and
xenograft mouse tumor models
To investigate the antitumor activity of embelin in vivo, matrigel
containing embelin (20 lM) or vehicle was mixed with murine B16-
F1 melanoma cells or human colon carcinoma LS174T cells and
injected into the flank of recipient mice. The growth rate of these
matrigel plugs was significantly attenuated in the presence of
embelin (Fig 1A). In a second approach, B16-F1 or LS174T cells
were subcutaneously injected into recipient mice. Animals received
intraperitoneal injections of embelin (8 mg/kg) or vehicle (controls)
every 48 h from the time of palpable tumor development. Embelin-
treated animals showed a significant reduction in tumor growth
after 3 weeks of treatment (Fig 1B).
Embelin treatment leads to reduced microvessel density in
murine tumor models
The tumor vasculature was analyzed in more detail for embelin-
mediated antiangiogenic effects. Assessment of the microvessel
density (MVD) in tumors of embelin-treated animals showed a
striking reduction compared with vehicle-treated controls (Fig 1C).
In addition, the average vessel diameter was significantly increased
compared to controls, suggesting the preferential regression of
smaller capillary vessels or structural vessel defects following
embelin treatment (Fig 1C). Following tail vein injection of high
molecular weight FITC-conjugated dextran, there was an increased
leakage into the interstitial space in B16-F1 xenografted mice, while
tumor vessels in LS174T tumors tended to be more leaky regardless
of embelin treatment (Fig 1C). However, we found no obvious
differences in pericyte coverage or basement membrane deposition
between embelin-treated animals and controls (Supplementary
Fig S1A). To investigate whether the reduced tumor growth was
the result of increased hypoxia and cell death, the tumor vessel
function was examined by injecting the hypoxia marker pimonidaz-
ole (2-nitroimidazole) into the tail vein of tumor-bearing mice.
Under hypoxic conditions, pimonidazole adducts form that can be
detected by immunohistochemistry. Overall, an increase in hypoxia
and cell death was observed owing to the reduction in MVD in
embelin-treated tumors (Fig 1D). Nevertheless, the lack of pimoni-
dazole adducts surrounding the residual tumor blood vessels in
embelin-treated animals indicated that these vessels were
adequately perfused and capable of carrying oxygen (and embelin)
into the nearby tumor tissue. In these perfused areas, there was also
no significant reduction in tumor cell proliferation (Ki67) or
increase in apoptotic cell death (caspase-3 staining), suggesting that
embelin did not directly inhibit tumor cell growth (Supplementary
Fig S1B). Consistent with this, matrigel plugs containing embelin
(20 lM) failed to be vascularized (Supplementary Fig S1C). These
analyses show that rather than targeting the tumor cells per se,
embelin attenuated tumor growth in vivo by targeting tumor blood
vessels leading to inadequate nutrient and oxygen supply and
ultimately a greater fraction of tumor cell death/necrosis.
Recently, CD105 (endoglin) expression has been correlated with
the proliferation rate of ECs in tissues participating in physiological
and pathological neoangiogenesis (Fonsatti et al, 2003; Lebrin et al,
2004). We found that tumors from embelin-treated mice showed a
disproportionate loss of CD105-positive ECs compared to controls,
suggesting that proliferating ECs rather than established quiescent
blood vessels were preferentially targeted by embelin treatment
(Supplementary Fig S1D). Importantly, we found no gross morphologi-
cal evidence of embelin-induced disruption of normal quiescent vascu-
lature in experimental animals (Supplementary Fig S1E), consistent
with its well-tolerated use in traditional medicine (Gupta et al, 1977).
To explore whether physiological processes such as wound
healing that require neoangiogenesis would also be affected by
embelin treatment, we investigated its effect on cutaneous wound
healing.
Embelin inhibits angiogenesis during wound healing in vivo
Full-thickness circular excisional wounds were inflicted on the
dorsum of C57/Bl6 mice. Animals were treated with embelin (8 mg/kg)
or vehicle by intraperitoneal injection every 48 h beginning 1 day after
wounding. Macroscopic wound closure was delayed in embelin-treated
mice as compared to vehicle-treated animals (Fig 2A). To assess dermal
repair, the amount and vascularization of granulation tissue was
examined in histological sections (Fig 2B and D). Unlike the highly
cellular and vascularized granulation tissue that normally develops
beneath the neoepidermis, embelin-treated animals showed only
scarcely vascularized granulation tissue (Fig 2D). Whereas in control
mice the microvessel density within the granulation tissue increased
during the healing response, in embelin-treated mice the number of
vessels was dramatically reduced (Fig 2E) and endoglin-positive
sprouting capillaries were almost absent (data not shown). Further-
more, the impaired development of vascularized granulation tissue
in embelin-treated animals was associated with a significant reduc-
tion in a-SMA-stained myofibroblasts and pericytes (Fig 2C) and a
delay in epithelialization (Fig 2B). On day 7 post injury, most control
wounds appeared completely epithelialized, whereas embelin-
treated wounds were still carrying a scab (Fig 2B). The distance
between the tips of the epithelial tongues was significantly larger in
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embelin-treated animals than in controls (Fig 2B and C) and the
formation of neoepidermis (i.e., the length of the epithelial tongues)
was significantly reduced on day 4 after injury (Fig 2C).
These findings demonstrate that systemic treatment with embelin
dramatically delayed neoangiogenesis and granulation tissue forma-
tion and attenuated wound closure kinetics. Given that the myeloid
compartment can influence pathological angiogenesis, detailed histo-
logical quantifications of polymorphonuclear neutrophils (GR1+) and
macrophages (CD68+) were conducted in punch wounds and in
B16-F1 tumors of immunocompetent animals (Supplementary Fig S2A
and B). However, no significant differences were observed in the
number of infiltrating macrophages or PMNs in response to embelin
treatment, making it unlikely that the antiangiogenic effects of
embelin treatment in wounds and tumors are secondary to alterations
in PMN and macrophage infiltration. Collectively, these observations
in the wound healing model corroborate the potent antiangiogenic
effects of embelin observed during tumor angiogenesis.
Embelin treatment targets ECs under growth condition
To better define the target cell population of embelin, we compared
its effect on ECs and non-ECs in vitro. The viability and clonogenicity
of primary EC cultures of human umbilical vein endothelial cells
(HUVECs) and human dermal microvascular endothelial cells
(HDMECs) was reduced at embelin concentrations far below those
required to induce similar effects in non-ECs such as tumor cells
and stromal cells including pericytes and fibroblasts (Fig 3A and B,
Supplementary Fig S3A and B).
Unlike proliferating blood vessels found in tumor tissue or during
wound healing, most established normal blood vessels are
comprised of ECs that are growth quiescent (Hanahan & Folkman,
1996). Our data summarized in Fig 1 and Supplementary Fig S1
indicate a specific cytotoxic effect of embelin toward angiogenic, but
not quiescent, ECs. To investigate this cytotoxic property of embelin
on proliferating versus quiescent ECs, quiescence was induced in
contact-inhibited confluent EC cultures of HUVECs and HDMECs by
growth factor depletion for 24 h as described previously (Mahboubi
et al, 2001; Kurz et al, 2003; Adams et al, 2005; Mariotti et al, 2006;
Vag et al, 2009). The quiescent phenotype was confirmed by appro-
priate changes in morphology, up-regulated VE-cadherin expression,
cell cycle arrest, reduced EdU incorporation, and down-regulation
of KI67 and CD105 expression (Fig 3C and D, Supplementary
Fig S3C and F). When exposed to embelin, only ECs under growth
conditions underwent rapid detachment and cell death, whereas
the quiescent ECs were refractory even after exposure for 24 h
(Fig 3E, Supplementary Fig S3G). The observed cytotoxicity was
non-apoptotic, as demonstrated by the lack of TUNEL staining,
caspase cleavage, and cytochrome c release (Fig 3F and Supplementary
Fig S3H and I). Accordingly, cell death could not be inhibited by the
pan-caspase inhibitor zVAD or the inhibitor of caspase-independent
programmed necrosis necrostatin (Fig 3F and Supplementary
Fig S3J). Finally, we investigated whether embelin induced auto-
phagic cell death. Indeed, we found that embelin treatment of ECs
leads to the conversion of LC3-I to LC3-II (Fig 3G and Supplemen-
tary Fig S3K); however, embelin-induced cell death was only mini-
mally affected when autophagy was inhibited with bafilomycin or
pepstatin, or by specific knockdown of ATG5 (Fig 3H). Further-
more, embelin-induced cell death preceded rapamycin-induced
autophagic cell death by almost 20 h (Fig 3H), suggesting that the
induction of autophagic cell death is not a major cytotoxic effect of
embelin. In summary, these data indicated that embelin treatment
preferentially induced non-programmed cell death in proliferating
but not in quiescent ECs, stromal, or tumor cells.
Embelin is a weak mitochondrial uncoupler that selectively
targets proliferating ECs
Although a range of cellular targets have previously been reported
for embelin’s antitumor activity—including ROS production
(Allensworth et al, 2012), suppression of NF-jB (Ahn et al, 2007),
and inhibition of XIAP (Nikolovska-Coleska et al, 2004)—at the
comparatively low concentrations required to induce EC cell death,
embelin did not induce ROS production (Supplementary Fig S4A),
did not alter NF-jB activity (Supplementary Fig S4B) nor did it affect
XIAP levels (Supplementary Fig S4C). In fact, siRNA-mediated XIAP
knockdown in ECs did not induce EC death.
However, previous biochemical studies have shown that benzo-
quinones including embelin can act as uncouplers of the mitochon-
drial membrane potential (MMP; Makawiti et al, 1990). We
therefore measured changes in the MMP in response to increasing
embelin concentrations and found that proliferating ECs were read-
ily depolarized by low concentrations of embelin, whereas quiescent
ECs and tumor cells were not readily uncoupled (Fig 4A and B and
Supplementary Fig S4D). Interestingly, EC stimulation with pro-
angiogenic growth factors (VEGF or FGF) further lowered the intrin-
sic MMP, thus sensitizing them to embelin-mediated uncoupling
and cell death (Fig 4C). Furthermore, embelin-induced cell death
could be restored even in quiescent ECs by re-exposing them to
growth factors underscoring the specific cytotoxicity of embelin
toward proliferating ECs (Fig 4D).
Of note, detailed time-course analysis demonstrated that the
depletion of the MMP clearly preceded cell death and was therefore
Figure 1. Embelin treatment attenuates tumor growth and tumor angiogenesis.
A The human colorectal cancer cell line LS174T or murine melanoma cell line B16-F1 was mixed with matrigel and embelin 20 lM or vehicle (controls) and injected s.c.
into recipient mice (n = 4). Tumor size was measured in 2 dimensions, and the calculated volume was recorded. Data points represent the mean ! s.d.
B LS174T cells or B16-F1 cells were injected subcutaneously into recipient mice (n = 5). Embelin was injected i.p. every 48 h after palpable tumors were detectable
(d10). Tumor size was measured in 2 dimensions, and the calculated volume was recorded. Data points represent the mean ! s.d.
C Immunofluorescence analysis of LS174T and B16-F1 tumors after a treatment period of 2 weeks with embelin or vehicle (Control), respectively, stained for vascular
endothelial cells (CD31 in red) and FITC-dextran (green). Quantification of microvessel density (MVD), vessel diameter, and leakiness. Data points represent the
mean ! s.d.
D Multiple image alignment of cryosections of LS174T and B16-F1 tumors treated as in (C). Areas of hypoxia were detected as pimonidazole adducts (green), and blood
vessels were stained with CD31 (red). (*) marks necrotic areas. Quantification of hypoxia and necrosis (lower panel). Necrosis is represented by a striped bar. Data
points represent the mean ! s.d. (n = 6).
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not a consequence of it (Supplementary Fig S4E). Furthermore,
another weak mitochondrial uncoupler, butylated hydroxytoluene
(BHT), also potently induced cell death in ECs under growth condi-
tions only (Fig 4E). Together, these data suggest that differences in
the mitochondrial respiratory performance of proliferating versus
quiescent ECs could be underlying their differential sensitivity
toward embelin.
We therefore examined the mitochondrial respiratory chain
performance. Both the basal and the specific respiration rates through
complexes I, II, and II/III were higher in proliferating than in quies-
cent ECs and tumor cells (Fig 4F and Supplementary Fig S4F and G),
indicating that proliferating ECs have a higher energy demand, which
they cover in large part by OxPhos. Under proliferating conditions,
HUVECs and HDMECs consumed three times more oxygen than
under basal conditions. Conversely, the respiratory reserve, that is,
the ability of electron transport to respond to a further increase in
energy demand, was lowest in proliferating HUVECs, suggesting that
they already operated near their bioenergetic limit (Fig 4F). The
lower inner membrane potential and low respiratory control ratio
measured in proliferating HUVECs is a direct consequence of the
greater utilization of the proton motif force by the ATP synthase, as
similar proton leak values were observed for all cell types, indicat-
ing similar coupling (Supplementary Fig S4H). Indeed, twice as
much ATP was produced in proliferating ECs compared to quiescent
ECs, and a much greater proportion (> 80%) of the ATP pool was
produced by OxPhos in proliferating ECs (Fig 4G). In contrast,
glycolytic ATP production in both cell types was not significantly
different.
Embelin treatment resulted in a further drop in the respiratory
control ratio and the MMP in both proliferating and quiescent
HUVECs; however, the complete depletion of the respiratory reserve
was only observed in proliferating ECs (Fig 4H). Following embelin
treatment, OxPhos-dependent ATP production became negligible
and the ATP content in proliferating ECs dropped to the level found
in quiescent ECs (Fig 4I). Despite the potential for increased glyco-
lytic ATP production (Supplementary Fig S4I), there was no signifi-
cant compensatory increase in glycolytic ATP production as
illustrated by a negligible increase in extracellular acidification
(ECAR) after embelin treatment (Fig S4J). Thus, the increased utili-
zation of the proton motif force combined with the limited respira-
tory reserve predisposes proliferating ECs to metabolic exhaustion
and cell death upon mitochondrial uncoupling. Indeed, similar effect
could be observed when mitochondrial ATP synthase was blocked
with oligomycin (Fig 4J). These findings suggest that the embelin-
induced cell death of ECs is the result of the inability of the mito-
chondria to meet ATP demand under growth conditions.
The increase in respiratory activity observed in proliferating ECs
compared with quiescent ECs prompted us to investigate the relative
dependence on glycolysis using oxamate, a substrate-like inhibitor
of lactate dehydrogenase (LDH), the enzyme that converts pyruvate
to lactate (Papaconstantinou & Colowick, 1961). Oxamate treatment
abolished lactate production in HUVECs (Supplementary Fig S4K)
and induced significant cell death in quiescent but not in proliferat-
ing ECs, demonstrating that quiescent ECs are more dependent on
glycolytic metabolism while illustrating the capacity of proliferating
ECs for mitochondrial metabolism of pyruvate via the Krebs cycle
(Fig 4K).
Mitochondrial dysfunction is associated with disrupted
angiogenesis in the mitochondrial DNA mutator mouse model
To independently demonstrate the important role of functional mito-
chondrial OxPhos in neoangiogenesis, we employed a genetic
mouse model for mitochondrial dysfunction and aging (Trifunovic
et al, 2004). This mouse model was engineered to have a defect in
the proofreading function of the catalytic subunit of mitochondrial
DNA (mtDNA) polymerase (POLGA), leading to the progressive,
random accumulation of mtDNA mutations associated with
impaired assembly and stability of the respiratory chain complexes
and a premature aging phenotype (Edgar et al, 2009). The first
premature aging symptoms, for example, slight kyphosis, alopecia,
and impaired weight gain, can be observed in mtDNA mutator mice
beginning at 25 weeks of age (Trifunovic et al, 2004). By contrast,
at 12 weeks of age, detailed and systematic assessment of mitochon-
drial respiratory activity revealed no obvious alteration (Trifunovic
et al, 2004). To investigate neoangiogenesis in these mice, matrigel
supplemented with VEGF and FGF was injected subcutaneously into
young (12-week-old) and aged (30-week-old) mtDNA mutator mice
and age-matched young and old wild-type mice. The animals were
injected with FITC-dextran after 11 days and matrigel plugs were
harvested. Macroscopic analysis showed that matrigel plugs from
young mutator mice aged between 10 and 12 weeks were as effi-
ciently vascularized as matrigel plugs from wild-type animals
(including young and old animals; Fig 5A upper panel). Further-
more, the endothelial networks formed in these plugs have a func-
tional lumen capable of conducting FITC-labeled dextran into the
matrigel plug (Fig 5A middle panel). In contrast, matrigel plugs
implanted into aged mutator mice (30 weeks) were barely vascular-
ized after 11 days, as evident from the macroscopic appearance and
lack of FITC-dextran signal. Histological analysis for CD31 expres-
sion confirmed the absence of new capillaries in the aged mtDNA
mutator mice, in contrast to the presence of new capillaries in plugs
Figure 2. Embelin attenuates the formation of vascular granulation tissue and delays wound healing.
A Punchwounds at the indicated time points post injury of embelin- or vehicle (control)-treatedmice. Wounds in controls, but not embelin-treatedmice, were almost completely
epithelialized on day 7 post injury, whereas in embelin-treated mice wounds still carry a scab; on day 10, arrowheads indicate scar tissue; scale bar, 500 lm.
B Schematic representation of wound histology on day 4 post injury and representative H&E-stained sections 4 days post injury; scale bar 100 lm.
C Morphometric analysis of wound tissue at different time points post injury; each dot represents one wound. The distance between the epithelial tips, the length of
the epithelial tongues, and the area of granulation tissue was measured.
D Immunofluorescence staining of CD31 and a-SMA in wounds of control and embelin-treated mice on day 7 post injury.
E Quantification of CD31 and a-SMA staining within granulation tissue; scale bar, 100 lm.
Data information: Dashed lines outline granulation tissue; dotted line indicates epidermal–dermal junction; arrows indicate tip of epithelial tongue; arrowheads indicate
ends of the injured panniculus carnosus at the wound edge; e, epidermis; he, hyperproliferative epidermis; d, dermis; gt, granulation tissue; sf, subcutaneous fat tissue.
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from young mutator and wild-type animals (Fig 5A lower panel). To
complement these analyses, we also show that established vascular
networks in retina and ear skin were not disrupted in old mutator
mice consistent with the specific dependency of neovessel formation
on mitochondrial function (Fig 5B). Together, these findings inde-
pendently support the concept that neoangiogenesis is critically
dependent on mitochondrial function and that disruption of mito-
chondrial function by pharmacological or genetic means can be
used to therapeutically target neoangiogenesis.
Discussion
Tumor growth and wound healing require the temporary activation
of quiescent ECs for the formation of new blood vessels. Unlike
quiescent ECs, angiogenic ECs are engaged in a number of energy-
consuming biological processes, such as proliferation, migration,
and capillary tube formation that may require metabolic adaptation
to cover the increasing energy demand. Indeed, recent evidence
suggests that a metabolic switch accompanies the proliferative
response during angiogenesis (De Bock et al, 2013a). In this study,
we demonstrated that neoangiogenesis can be inhibited in mouse
models of tumor growth and cutaneous wound healing by targeting
mitochondrial oxidative metabolism both pharmacologically and in
a genetic mouse model.
All cells must respond to changes in the availability of substrates
for energy metabolism in order to survive. When glucose is scarce—
as can occur in solid tumors—ECs are forced to change from gener-
ating ATP predominantly by glycolysis to OxPhos using alternative
energy substrates that can be oxidized by the mitochondria includ-
ing glutamine, lactate (Parra-Bonilla et al, 2010), and fatty acids
(Dagher et al, 2001). Oxidative metabolism in ECs is inhibited at
physiological concentrations of glucose, a phenomenon known as
the Crabtree effect (Kru¨tzfeldt et al, 1990), however, this is not the
case at the low glucose levels experienced in the tumor microenvi-
ronment (Hirayama et al, 2009). Indeed, we show that proliferating
HUVECs and HDMECs consume three times more oxygen than
quiescent ECs and work close to their respiratory limit. It has previ-
ously been demonstrated that in addition to serving as a conduit for
the delivery of oxygen, the microvasculature itself consumes a
significant amount of oxygen (Tsai et al, 1998). To sustain EC prolif-
eration in the absence of extracellular glucose, lactate secreted from
glycolytic tumor cells is sufficient to restore ATP levels and partially
rescue EC growth, suggesting that lactate is converted into pyruvate
for mitochondrial respiration (Parra-Bonilla et al, 2010). In addition,
fatty acid oxidation can support EC proliferation and the disruption
of fatty acid handling limits EC proliferation (Elmasri et al, 2009).
But even in the absence of exogenous substrates, ECs can oxidize
endogenous amino acids or lipids (Mertens et al, 1990; Dagher et al,
2001). Consistent with an increased utilization of OxPhos, proliferat-
ing ECs become less dependent on glycolytic elimination of pyru-
vate. This is illustrated by our finding that oxamate, a substrate
inhibitor of LDH, induced significant cell death in quiescent, but not
in proliferating, ECs (Fig 4K). LDH permits the rapid consumption
of pyruvate, regenerating NAD+ to sustain the glycolytic flux while
yielding a product (lactate) that can easily be secreted. This permits
the generation of glycolytic energy when OxPhos activity is low by
avoiding pyruvate accumulation. Therefore, the susceptibility to
LDH inhibitors is increased in cells with predominantly glycolytic
metabolism, whereas cells with increased OxPhos activity are
independent of LDH activity as they can feed pyruvate into the
Krebs cycle.
Our detailed metabolic analysis of embelin identifies it as a bona
fide, however, weak uncoupler of the MMP, which is capable of
dissociating electron flow from ATP synthesis, thus exhausting the
already limited respiratory reserve of proliferating ECs. Importantly,
other weak mitochondrial uncouplers such as BHT also induce cell
death in proliferating but not in quiescent ECs, further supporting
the evidence that the antiangiogenic activity of embelin is due to its
activity as a mitochondrial uncoupler. While the use of mitochon-
drial uncouplers in patients is not unprecedented, the narrow thera-
peutic window of conventional uncouplers led to the abandonment
of their official use in the treatment of obesity (Harper et al, 2001).
However, BHT has been shown to partially uncouple mitochondria
over a wide dynamic range (the difference between therapeutic and
toxic doses), thus presenting a more promising therapeutic opportu-
nity (Lou et al, 2007).
The transition from resting (slow respiring) state 4 to phosphory-
lating (fast respiring) state 3 is associated with an increased utiliza-
tion of the proton motif force by the mitochondrial ATP synthase
Figure 3. Embelin treatment disrupts endothelial cell function and survival in vitro.
A Measurement of cell viability of human umbilical vein endothelial cells (HUVECs), human dermal microvascular endothelial cells (HDMECs), LS174T and B16-F1,
fibroblasts and pericytes in response to embelin treatment. Viability was assessed by trypan blue exclusion after embelin treatment for 3 h.
B Measurement of clonogenicity of cell lines as in (A). Clonogenicity was assessed by crystal violet staining of adherent colonies 14 days after exposure to embelin.
C Detection of EdU incorporation in proliferating and quiescent HUVECs. Proliferating cells are stained green. Nuclei were counterstained with DAPI (blue, upper panel).
Quantification of EdU incorporation by FACS analysis. Data points represent the mean ! s.e.m. (n = 3; lower panel). MFI, mean fluorescence intensity; scale bar,
200 lm.
D FACS analysis of CD105 expression in quiescent and proliferating HUVECs. RFI, relative fluorescence intensity.
E Phase-contrast microscopy images of quiescent and proliferating cultures of HUVECs and HDMECs after embelin treatment for 3 h; scale bar, 200 lm.
F Cell death was measured by trypan blue exclusion assay in proliferating and quiescent HUVECs or HDMECs (left panel). Propidium iodide (PI) and TUNEL staining
were measured in proliferating HUVECs and HDMECs in response to embelin by FACS analysis (middle panel). Cell death was measured by trypan blue exclusion in
the presence or absence of zVAD (right panel; n = 3).
G LC-3 conversion was analyzed in total cell lysates after treatment with embelin (5 lM) or rapamycin (40 mg/ml) at the indicated time points.
H Cell death measured by trypan blue exclusion in proliferating HUVECs following treatment with embelin (5 lM), pepstatin (10 lg/ml), bafilomycin (160 nM), or
combinations as indicated (left panel), or following specific knockdown of ATG5 or transfection with scrambled (scr) siRNA (center panel), or following treatment with
embelin (5 lM) or rapamycin (40 mg/ml; right panel; n = 3).
Source data are available online for this figure.
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leading to a decrease in the MMP (Chance & Williams, 1956; Yuan
et al, 1996). Accordingly, pro-angiogenic growth factors such as
VEGF or FGF induce a further reduction in the intrinsic MMP in
proliferating ECs that predisposes them to mitochondrial uncoupling
and cell death (Fig 4C). Remarkably, quiescent ECs can be re-sensi-
tized to embelin-induced cell death by exposure to angiogenic
growth factors, as might occur in the context of tumor growth or
wound healing (Fig 4D). Consistent with this, embelin preferentially
targets proliferating endoglin-expressing blood vessels rather than
mature quiescent vasculature (Supplementary Fig S1D). In contrast,
most normal blood vessels under physiological conditions are
growth quiescent and therefore resistant to embelin treatment. From
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a clinical perspective, this is important because the selective target-
ing of neoangiogenesis could help to restrict tumor growth without
adversely impacting on quiescent normal blood vessels or mature
tumor vessels potentially required for the delivery of cytostatic
chemotherapy.
Sprouting blood vessels are made up of different cell populations:
leading tip cells, which guide the sprout, and trailing stalk cells,
which proliferate to elongate the stalk (De Smet et al, 2009).
Recently, De Bock et al showed the important role of glycolytic
metabolism in sprouting angiogenesis. Specifically, overexpression
of the glycolytic activator PFKFB3 could induce sprouting tip cell
behavior even in proliferating stalk cells (De Bock et al, 2013b).
This is a remarkable finding, because it shows that metabolic regu-
lators are directly involved in EC phenotype decisions, demonstrat-
ing an unprecedented degree of metabolic control during
angiogenesis. In contrast to tip cells, PFKFB3 expression, and there-
fore glycolytic energy production, is normally inhibited in prolifer-
ating stalk cells by Notch activation (De Bock et al, 2013b),
suggesting that alternative energy sources such as OxPhos may be
employed to cover the increasing energy demand during EC prolif-
eration. Accordingly, oxamate failed to induce cell death in prolif-
erating ECs (Fig 4K), whereas the inhibition of mitochondrial
OxPhos with oligomycin or uncoupling of mitochondria with
embelin or BHT leads to the depletion of ATP (Fig 4I) and cell
death in proliferating, but not in non-proliferating, ECs (Fig 3F, 4E
and J). Interestingly, the proliferating endothelial stalk cells
express high levels of the metabolic sensor SIRT1 (Potente et al,
2007) and SIRT1 is also expressed at elevated levels in proliferat-
ing rather than in quiescent HUVECs along with other regulators of
OxPhos (Supplementary Fig S4L). SIRT1 activation redirects cellu-
lar metabolism from glycolysis to OxPhos by deacetylating and
activating transcription factors and cofactors, such as peroxisome
proliferator-activated receptor-c coactivator-1a (PGC-1a) (Rodgers
et al, 2005). Therefore, tip and stalk cells may use different energy
production pathways. Balancing between glycolytic and mitochon-
drial energy production, regulated by Notch and SIRT1, might be
critical in the proliferating stalk cells, whereas glycolytic energy
production appears to be predominant in the migrating tip cells
(Harjes et al, 2012).
Further evidence for the critical role of functional mitochondrial
OxPhos during neoangiogenesis is provided by the impairment of
neovascularization in matrigel plugs in mtDNA mutator mice. These
mice serve as models of mitochondrial dysfunction and aging as
they express defective mtDNA polymerase and progressively accu-
mulate mutations in mtDNA. Measurable alterations in the mito-
chondrial respiratory activity start occurring after 25 weeks of age
(Trifunovic et al, 2004). Prior to 25 weeks of age, there is no appar-
ent phenotype or tissue defect in these mice (Trifunovic et al, 2004,
2005; Niu et al, 2007). Given that all of the proteins encoded by
mitochondrial genes are involved in OxPhos (Anderson et al, 1981),
it is tempting to speculate that the failure to recruit vascular ECs to
the matrigel plugs is due to energetic collapse and that functional
mitochondrial activity is necessary for the formation and/or recruit-
ment of new blood vessels (Fig 5). While the “mutator” model is
not without limitations and systemic tissue dysfunction (even if not
obvious at this age) might in principle contribute to the phenotype
observed in these animals, bone marrow-derived myeloid cells that
have an important role in regulating the formation and maintenance
of blood vessels in tumors appear to be unaffected in this mouse
model (Norddahl et al, 2011). Furthermore, despite severe respira-
tory chain dysfunction, the premature aging phenotype is not
caused by alterations in ROS production or oxidative stress, both
potential drivers of angiogenesis (Trifunovic et al, 2005).
While recently the important role for glycolysis has been
explored in sprouting angiogenesis, our findings demonstrate that
other metabolic pathways also influence vessel formation. Specifi-
cally, mitochondrial targeting of proliferating ECs could be clinically
valuable to control pathological neoangiogenesis and complement
cytostatic drugs in cancer treatment, while minimizing collateral
damage to normal quiescent ECs.
Materials and Methods
Cell lines, cell culture
The human colon carcinoma cell line LS174T, the murine melanoma
cell line B16-F1, and the human colonic epithelial cell line (CoTr)
Figure 4. Embelin is a mitochondrial uncoupler that specifically targets proliferating endothelial cell.
A Structure of the benzoquinone embelin and quantification of the mitochondrial membrane potential (MMP) in proliferating human umbilical vein endothelial
cells (HUVECs), human dermal microvascular endothelial cells (HDMECs), LS174T, and B16-F1 cells in response to embelin by FACS analysis of TMRE-stained cells.
B Fluorescence analysis of proliferating or quiescent HUVECs, LS174T, and B16-F1 in response to embelin, stained with MitoTracker-Red. Nuclei were counterstained
with DAPI; scale bar, 20 lm.
C Quantification of the MMP (left panel) and cell death (right panel) in proliferating HUVECs stimulated with VEGF (20 ng/ml) or FGF (20 ng/ml) or embelin (5 lM) for
24 h and analyzed by FACS of TMRE-stained cells or trypan blue exclusion, respectively (n = 3).
D Quiescent HUVECs were stimulated overnight with VEGF (20 ng/ml). Cell death was measured in proliferating, quiescent, and “restimulated” proliferating cells in
response to embelin (5 lM). Data points represent the mean ! s.e.m. (n = 3).
E Measurement of cell viability of proliferating and quiescent HUVECs in response to the indicated concentrations of butylated hydroxytoluene (BHT). Viability was
assessed by trypan blue exclusion. Data points represent the mean ! s.e.m. (n = 3).
F Respiratory activity in proliferating and quiescent HUVECs, LS174T, and B16-F1 (left panel) and indices of mitochondrial performance (respiratory reserve, MMP,
respiratory control ratio; n = 3).
G ATP production by oxidative phosphorylation (OxPhos) or glycolysis was measured in proliferating and quiescent HUVECs with or without embelin (5 lM) treatment
for 30 min (n = 3).
H Impact of embelin treatment on mitochondrial performance of proliferating versus quiescent HUVECs (n = 3).
I ATP content was measured in proliferating and quiescent HUVECs with or without embelin (5 lM) treatment for 50 min (30 min at 37°C, 20 min at RT; n = 3).
J Measurement of cell viability of proliferating and quiescent HUVECs in response to the indicated concentrations of oligomycin. Viability was assessed by trypan blue
exclusion (n = 3).
K Measurement of cell viability of proliferating and quiescent HUVECs in response to the indicated concentrations of oxamate. Viability was assessed by trypan blue
exclusion (n = 3).
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were purchased from ATCC (Bethesda, Maryland, USA); human
primary melanoma cells (MOO1 and HOM1) and human dermal
fibroblasts were a gift of Dr C. Mauch (Department of Dermatology,
University of Cologne, Germany). LS174T, MOO1, and HOM1 cells
were maintained in RPMI 1640 supplemented with 10% fetal calf
serum (FCS), 2 mM L-glutamine, 100 lg/ml streptomycin, and
100 U/ml penicillin (all from Biochrom, Berlin, Germany). B16-F1,
CoTr, and fibroblasts were maintained in DMEM supplemented with
10% FCS, 2 mM L-glutamine, 100 lg/ml streptomycin, and 100 U/ml
penicillin (Biochrom). HUVECs, HDMECs, and human pericytes
(hPC-PL) were purchased from Promocell (Heidelberg, Germany) and
maintained in EC growth medium between passages 2–5. Quiescence
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Figure 5. Neoangiogenesis is impaired in mtDNA mutator mice.
A Matrigel was injected s.c. into recipient control and mutator mice 12 weeks (young) or 30 weeks (old) of age. Photograph of the plug after 11 days (upper panel).
FITC-dextran is shown in green (middle panel). Microscopic analysis of CD31 (red) and DAPI (lower panel); scale bar, 5 mm.
B Microscopic analysis of FITC-dextran in retina and ear skin of young (12 weeks) or old (30 weeks) wild-type and mutator mice treated as in (A); scale bar, 200 lm.
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was induced in confluent HUVECs and HDMECs by cultivation
in basal EC medium depleted of growth factors (Promocell) for
36 h.
Ethics statement
All animal experiments were performed in accordance with the
German animal protection law. Institutional Animal Care and Use
Committee approval was obtained for all animal studies.
Animal tumor models
C57BL6/J and Balb/cA nude mice were purchased from Charles
River (Sulzfeld, Germany). Human colorectal cancer cells LS174T
(3 × 106) or murine melanoma cells B16-F1 (1 × 106) were injected
subcutaneously into the flank region of 6- to 8-week-old BALB/cA
nude mice or C57/Bl6, respectively. In the treatment group, embelin
8 mg/kg (Biotrend, Cologne, Germany) was freshly dissolved in
vehicle (10% DMSO, 100 mM Tris–HCl, pH 7.4) and administered
by intraperitoneal injection every 48 h. The control group received
injections of vehicle only. For the matrigel plug assay, 400 ll of
chilled matrigel (BD Bioscience, Heidelberg, Germany) was mixed
with 3 × 106 LS174T or 1 × 106 B16-F1 tumor cells and embelin (at
a final concentration of 20 lM) at 4°C for subcutaneous injection
into recipient mice. Tumor size was measured every other day using
precision calipers. Tumor volume was calculated as length ×
width2 × p⁄6 and expressed as average ! s.e.m. Animals were
housed in the animal care facility of the University of Cologne under
standard pathogen-free conditions with a 12-h light/dark schedule
and provided with food and water ad libitum.
Mutator mouse experiments
Four hundred microliters of chilled matrigel (BD Bioscience) was
injected into 12- or 30-week-old mutator mice (Trifunovic et al,
2004). After 11 days, mice were sacrificed and the matrigel was
removed, fixed in 4% paraformaldehyde (PFA) for microscopic
analysis or prepared for further downstream analyses.
Images of matrigel plugs
Images were taken using a motorized Leica M165 FC fluorescent
stereomicroscope equipped with DFC490 CCD camera and GFP2
(Ex. 480/40 nm) filter set. Images were processed using the Multi-
focus module of LAS 3.7.0 software (Leica).
Cutaneous wound healing assay
Four full-thickness paravertebral punch-biopsy wounds were
induced on the shaved dorsum of 12-week-old C57BL6/J mice under
Ketanest/Rompun anesthesia (Ketanest 100 mg/kg body weight,
Park Davies, Karlsruhe; Rompun 2%, 1 ml/kg body weight; Bayer,
Leverkusen, Germany). For each time point and condition, 2–3
animals were used. Beginning on day 1 after wounding, animals in
the treatment group received intraperitoneal injections of embelin at
8 mg/kg or vehicle (10% DMSO, 100 mM Tris–HCl, pH 7.4) in the
control group every 48 h over the treatment period. For histological
analysis, animals were sacrificed and wound tissues were harvested
on days 4, 7, or 10 after wounding. Wound tissue was excised and
the wound area bisected in caudocranial direction and the tissue
was either fixed overnight in 4% PFA in phosphate-buffered saline
(PBS) or embedded in optimal-cutting-temperature O.C.T.
compound (Tissue-Tek; Sakura Finetek, Staufen, Germany). Histo-
logical analysis was performed on serial sections (5-lm cryosec-
tions) from the central region of the wound.
Morphometric analysis of wounds
Morphometric analysis was performed on digital images using the
Imaging Software Lucia G 4.80 (Laboratory Imaging Ltd., Prague,
Czech Republic). Microscopy of punch wounds was conducted
using a Microscope Eclipse 800E (Nikon, Du¨sseldorf, Germany).
The extent of epithelization and granulation tissue formation was
determined on hematoxylin/eosin (H&E)-stained paraffin tissue
sections as previously described (Lucas et al, 2010). The length of
the epithelial tongue was determined as the distance between the
epithelial tip and the margin of the wound as defined by the pres-
ence of hair follicles in non-wounded skin. This parameter reflects
the formation of neoepithelium. In addition, the width of the gap
between the epithelial tips reflects wound closure. Granulation
tissue was defined as the cellular and vascular tissue that formed
underneath the neoepithelium and between the wound margins and
above the subcutaneous fat tissue. For quantitative analysis of CD31
or a-SMA expression, the area of three high-power fields (HPF) that
stained positive for CD31 or a-SMA within the granulation tissue
was calculated.
Histology and microscopy
Tumor tissue samples were snap-frozen in O.C.T. for storage and
further processing. Fresh cryosections of tumors (20 lm) were
prepared and fixed in 3% PFA for 10 min, followed by incubation in
blocking solution (10% normal goat serum; Invitrogen, Karlsruhe,
Germany) and incubation with appropriate primary and secondary
antibodies. Cryosections of cutaneous punch wounds (5 lm) were
fixed in acetone, endogenous peroxidase was inactivated (0.03%
H2O2, 0.15 M NaN3), and unspecific binding sites were blocked with
3% BSA in PBS. Cells were seeded for microscopy on cover slips
and fixed with 3% PFA and permeabilized in PBS/0.1% saponin.
After blocking (3% BSA/0.1% saponin in PBS), cells were incubated
with the appropriate antibodies. Sections were mounted in Mowiol
mounting medium (Calbiochem, Schwalbach, Germany) and exam-
ined with a motorized inverted microscope (Olympus IX81 or IX71
equipped with Cell^R Imaging Software; Tokyo, Japan) using a 60×/
1.45 numerical aperture Planapo oil objective.
Immunohistochemistry
ECs were stained with rat monoclonal anti-mouse CD31 antibody
(PEACAM-1; clone MEC 13.3, 1:500; BD Pharmingen, Heidelberg,
Germany) and detected using an Alexa Fluor 488-conjugated poly-
clonal goat anti-rat antibody (1:500; Invitrogen). Proliferating ECs in
tumor tissue were stained with a rat anti-mouse CD105 (endoglin)
PE-conjugated monoclonal antibody (1:500, clone: MJ7/18; eBio-
science, Frankfurt am Main, Germany). Perivascular cells were
stained with Cy3-conjugated mouse monoclonal anti-a-smooth
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muscle actin antibody (1:1,000, a-SMA clone 1A4; Sigma-Aldrich,
Munich, Germany). Mitochondrial morphology and membrane
potential were visualized by MitoTracker (RedCMXRos) staining
(Invitrogen). For cytochrome c staining, a mouse monoclonal anti-
cytochrome c antibody was used (1:500; clone 7H8.2C12; BD
Biosciences) and detected with a secondary Alexa Fluor 488-conju-
gated polyclonal goat anti-mouse antibody (1:500; Invitrogen). For
VE-cadherin staining, a monoclonal rabbit anti-VE-cadherin anti-
body (clone D87F2; Cell Signaling) was used and detected with a
secondary Alexa Fluor 488-conjugated polyclonal goat anti-rabbit
antibody (1:500; Invitrogen).
Vascular perfusion, leakiness, hypoxia studies
For vessel perfusion and leakiness studies, 200 ll of FITC-dextran
(15 mg/ml in PBS, MW 2,000,000; Sigma-Aldrich) was injected into
the tail vein of tumor-bearing mice 30 min before animals were
sacrificed. All tumors were excised and snap-frozen in O.C.T for
storage and further processing. Vessel leakiness was analyzed using
100× images of tumors from FITC-dextran-injected mice and the
percentage of leaky vessels (identified by extravasation into the
surrounding tumor tissue) among perfused vessels (dextran- and
CD31-positive) was determined. Non-perfused vessels were not
included. At least four tumors per group and 5–9 images were used,
depending on tumor size.
Cell viability and cell death measurements
Cells were harvested after treatment and viability was quantified
by trypan blue exclusion using an automated cell counter (Count-
ess; Invitrogen) according to the manufacturer’s instructions. Cell
death was quantified by FACS analysis (FACS-Canto; BD Bioscienc-
es) of cells stained with propidium iodide (PI) (0.1 lg/ml in PBS)
for 5 min. Alternatively, cells were stained for FACS analysis by
the LIVE/DEAD Far Red Dead Cell Stain Kit “NH2 Assay” (Invitro-
gen) according to the manufacturer’s instructions. Apoptosis was
assessed by terminal deoxynucleotidyl transferase dUTP nick-end
labeling (TUNEL) using the APO-DIRECTTM Kit (BD Pharmingen)
according to the instructions of the manufacturer. Data points
represent mean values from at least three independent
experiments.
Clonogenicity assays
1 × 104 cells per well were seeded in 6-well plates and allowed to
settle. Cells were then transiently exposed to embelin at the indi-
cated concentrations for 24 h. After recovering for 10 days in fresh
medium without embelin, colony formation was assessed by crystal
violet staining. Cells were washed in PBS, stained with crystal violet
(0.2% in 2% EtOH), and dissolved in 0.2 M sodium citrate and
100% EtOH (1:1).
Analysis of quiescence by CD105 quantification
Loss of CD105 (endoglin) expression in quiescent ECs was quanti-
fied using an APC-conjugated anti-human CD105 antibody (Clone:
SN6; eBioscience) by flow cytometry using a FACS-Canto (BD
Biosciences).
Cell cycle analysis
Cell cycle analysis was performed by assessment of the DNA content
using propidium iodide. Briefly, cells were fixed using 3% PFA and
treated with 100 lg/ll RNase A (ThermoScientific) in PI containing
staining buffer (APO-DIRECTTM Kit; BD Pharmingen) for 4 h at
37°C. DNA content was assessed by flow cytometry (FACS Calibur,
BD) and further evaluated with flow jow. Data are presented as
means ! s.e.m. from at least three independent experiments.
Cell proliferation analysis
Cell proliferation analysis was performed by the assessment of
incorporated EdU using the Click-iT EdU Alexa Fluor 488 Imaging
Kit or the Click-iT Edu Alexa Fluor 647 Flow Cytometry Assay Kit
(Molecular Probes, LifeTechnologies) according to the manufac-
turer’s instructions. Cells were incubated with EdU for 48 h,
followed by staining and analysis by microscopy or by flow cytome-
try, respectively. Data are presented as means ! s.e.m. from at least
three independent experiments.
Respiratory chain performance
Basal oxygen consumption of intact cells, reflecting the metabolism
of endogenous substrates, was measured shortly after harvesting
using a Clark electrode (Hansatech Instruments Limited, King’s
Lynn, UK). Following permeabilization with digitonin (0.01%), the
oxidation rates of the respiratory chain substrates pyruvate (10 mM,
in the presence of 1 mM malate, MPOX), malate (10 mM, in the
presence of 10 mM glutamate, MGOX), succinate (10 mM, SOX),
and glycerol-3-phosphate (20 mM, GPOX) were determined. To esti-
mate respiration coupled to ATP synthesis, oligomycin (10 lM) was
added to inhibit the ATP synthase (complex V). The resulting
decrease in respiration rate allows us to calculate the oxygen
consumption associated with ATP generation. The remaining respi-
ration rate is an indirect, however, valuable indicator of the proton
leak across the mitochondrial inner membrane. The maximal respi-
ratory capacity was estimated by measuring the respiration rate in
the presence of the uncoupler FCCP (10 lM). These data were used
to calculate a respiratory control ratio and the reserve capacity. This
respiratory control ratio reflects the integrity of the inner membrane
and was calculated as the ratio of maximal respiratory capacity to
proton leak (Rustin et al, 1994), whereas the reserve capacity for
mitochondrial bioenergetic function was calculated by subtracting
the basal respiration rate from the maximal rate.
Oxygen consumption measurements
Measurement of intact cellular respiration was performed using the
XF24 analyzer (Seahorse Bioscience). Cells were treated with 5 lM
embelin for 30 min. Prior to the respiration assay, cells were rinsed
and cultured in assay medium supplemented with 5 mM glucose,
10 mM sodium pyruvate (Sigma), 2 mM glutamate, and 3% FCS
according to the manufacturer’s protocol. Cells were incubated at
37°C in a CO2-free incubator for 1 h prior to measurement. Oxygen
consumption rate (OCR), extracellular acidification rate (ECAR),
and proton production rate were measured under basal conditions
and in the presence of oligomycin, a complex V inhibitor (1 lg/ml),
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the complex III inhibitor antimycin (2.5 lM), and mitochondrial
uncoupler FCCP (3 lM; Sigma) to assess maximal oxidative capacity.
After respiration assay, media were aspirated, wells were washed
once with PBS, 25 ll of M-Per lysis buffer (Thermo Scientific) was
added, and lysates were analyzed for total protein content using BCA
assay (Pierce, Thermo Scientific). Data were normalized to total
protein content, and a number of parameters were assessed (Brand &
Nicholls, 2011) subsequent to the subtraction of non-mitochondrial
respiration (NMR) from each value. ATP production by OxPhos
was calculated by multiplying ATP turnover [(basal OCR " NMR)—
(oligomycin-inhibited OCR " NMR)] by the established phospho-
rus/oxygen (P/O) ratio of 2.3 (Brand, 2005). ATP production by
glycolysis is considered to have a 1:1 ratio with lactate production,
which is measured by PPR (Birket et al, 2011). Respiratory reserve
capacity = (maximal OCR " NMR) " (basal OCR " NMR).
Titration with oligomycin
Cell changes in OCR and ECAR were measured on Seahorse XF24 in
response to addition of oligomycin in consecutive injections that
produced final concentrations of 0.08, 0.4, 0.2, and 1 lM. OCR and
ECAR changes were normalized to untreated baseline.
ATP content
ATP levels in viable cells were quantified using CellTiter-GloTM
Luminescent Cell Viability assay kit (Promega) according to the
manufacturer’s instructions. Lyophilized enzyme/substrate mixtures
(100 ll) were transferred to opaque 96-well microplates containing
cell lysates. The microplates were then incubated at room tempera-
ture for 10 min to stabilize luminescence signals, which were then
measured using a Tecan GENios Microplate Reader.
Mitochondrial membrane potential
The inner membrane potential was estimated using JC-1 as a fluo-
rescent indicator. Cells were incubated with JC-1 (2 lM) for 15 min,
and the ratio of green monomer (514-/529-nm excitation/emission
maxima) to red J-aggregate (585-/590-nm excitation/emission
maxima) was determined by flow cytometry using a FACSCanto
cytometer equipped with BD FACSDiva software (Becton Dickinson,
Heidelberg, Germany).
Assessment of proliferation and hypoxia
For tumor cell proliferation, a rabbit Ki67 polyclonal antibody (1:200;
Menarini Diagnostics, Berlin, Germany) was used. For hypoxia stud-
ies, 200 ll of pimonidazole hydrochloride (15 mg/ml; Artimmun-
Analytik GmbH, Kelkheim, Germany) was injected into the tail vein
of tumor-bearing mice 30 min before animals were sacrificed by cervi-
cal dislocation. The formation of pimonidazole adducts in hypoxic
tumor areas was detected with a FITC monoclonal anti-pimonidazole
antibody (1:50, clone 4.3.11.3; ArtimmunAnalytik GmbH).
siRNA-mediated knockdown
Proliferating HUVECs were transiently transfected with specific
XIAP-siRNAs (1: 50-GGGUUUCUUUAUACUGGUGTT-30; 2: 50-GGA
AUAAAUUGUUCCAUGCTT-30) or non-targeting control (scr) with
Lipofectamine RNAiMAX Transfection Reagent (Invitrogen) according
to the manufacturer’s instructions. Cell viability measurements were
performed after 48-h incubation.
Western Blotting
Whole-cell extracts of proliferating or quiescent HUVECs were
prepared by cell lysis in CHAPS buffer (10 mM HEPES pH 7.4,
150 mM NaCl, 1% CHAPS) complete protease inhibitor cocktail
on ice for 20 min. Proteins were separated by SDS–PAGE prior
to transfer onto nitrocellulose membranes (Protran; Schleicher &
Schuell, Dassel, Germany). The following primary antibodies
were used in Western blotting: human caspase-9 and caspase-3
(clone 8G10; BD Biosciences), Sirt1 (clone 3H10.2; Millipore),
PKM1 (Proteintech), PKM2 (clone D78A4; Cell Signaling),
XIAP (clone 48; BD Biosciences), LC3B (clone D11; #3868; Cell
Signaling).
ROS measurement
For the measurement of mitochondrial ROS production, proliferating
HUVECs were incubated with 5 lM MitoSOXTM Red mitochondrial
superoxide indicator (M36008; Molecular Probes, Invitrogen) at
37°C for 10 min. Cell were washed three times and analyzed by
FACS analysis.
The paper explained
Problem
There is a huge difference between normal and tumor ECs in terms of
proliferation rate and metabolic activity. Such a universal difference is
rare in cancer biology. On this basis, the rapidly dividing ECs lining
the blood vessels represent an attractive target for cancer treatment.
Any compound capable of inducing cell death rather selectively in
such proliferating ECs would therefore be valuable in the develop-
ment of antiangiogenic and thus potentially antitumorigenic drugs. In
this manuscript, we provide a novel concept for disrupting tumor
neoangiogenesis by targeting mitochondrial activity in angiogenic ECs.
Results
The benzoquinone embelin acts as a weak mitochondrial uncoupler,
and this prevents energy-intensive processes such as proliferation,
migration, and capillary tube formation that are indispensible for
neoangiogenesis during tumor growth and wound healing. By
exhausting the intrinsically low respiratory reserve of proliferating
ECs, embelin impairs the angiogenic capacity of proliferating ECs by
depleting their energy reserves without adversely affecting quiescent
ECs. This useful property was exploited therapeutically to inhibit
tumor growth in syngenic and xenograft mouse tumor models and
during wound healing. To validate mitochondrial targeting in this
context, we demonstrate that neoangiogenesis is impaired in mtDNA
mutator mice with defective mitochondrial respiration.
Impact
Weak mitochondrial uncoupling agents that target proliferating ECs
could be clinically valuable to control pathological neoangiogenesis
and complement cytostatic drugs in cancer treatment, while minimiz-
ing collateral damage to normal quiescent ECs.
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NF-jB activity
ELISAs were performed after nuclear extraction using the TransAM
Nuclear Extract Kit and the TransAM NFjB p65 Kit (Active motif)
according to the instructions of the manufacturer. Read out was
performed on an ELISA reader (Anthos HT2) at a wavelength of
450/620 nm.
Statistical analysis
Results are given as means ! s.d. and were compared using
unpaired t-tests assuming unequal distribution. A significance level
of < 0.05 was considered to be statistically significant; *P < 0.05;
**P < 0.01; ***P < 0.001.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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